about
MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.Toward the molecular dissection of peritoneal pseudomyxoma.Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study.Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.RET fusions in a small subset of advanced colorectal cancers at risk of being neglected.Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.Duration of first-line treatment for metastatic colorectal cancer: Translating the available evidence into general recommendations for routine practicePerioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver MetastasesEstimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life NomogramPrognostic impact of ATM mutations in patients with metastatic colorectal cancerAssessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialBenefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept studyIncidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trialsTemozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylationBilateral parotid gland metastases from gastric signet-ring cell carcinomaWhole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patientsA Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI TraitsPerioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver MetastasesRefining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferaseCapecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal CancerClinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials
P50
Q27853393-C7D2A5F2-FBFD-4506-AFC2-6085C82E61B5Q27853397-2505EB47-5596-4009-BF6B-9FF115B87A3FQ37115074-7F249181-E2BF-401F-9B63-42421624538EQ38377594-8B230561-4EAD-4BDC-B699-82964D292C67Q38631105-B633292A-A9DE-492F-A239-249153E711F9Q38706872-0521AACF-1E45-4013-B04A-65CE498042FAQ38801281-6578300C-995D-4252-A9D7-A9BCBABAE3C6Q44896094-B9DCD17A-6FE3-4462-A9C5-9F6618D06BE2Q48523391-16FC6C42-0A46-46E1-9A3F-F732964DD04AQ49551908-EB6BC3B1-44AE-4E9F-9B8C-AD7F78CDC0EEQ49691234-BF90A8B3-31A3-4DDB-BBDE-914FED95C3AFQ50058854-691F3574-8FE5-4B1C-A97F-A5DAE8E01D95Q50089419-FDE8C289-0C77-4183-A613-179F19EE8AB1Q50206050-449F95BC-BB7D-4872-8DD4-BCACEC6E1590Q51541370-BE7397FA-8EED-4765-8CD6-FA72F3786291Q52628875-0DF9F625-BAAA-42DB-A591-289A7E272034Q52655893-ABE71DB4-343E-4438-AD6A-40CB9E64F619Q52659461-A775597A-76D3-4DCB-9453-BA2E70C18633Q52905730-9CDCDFB4-F243-4981-9011-E3A8C7686747Q55689035-79B8B81B-8C50-4295-BB34-317998F160B0Q57181163-B149E8C5-CB65-4421-80A5-B7B1BA62136EQ58199964-2777526E-C1F2-4C8A-AA93-81C8893C779BQ61054483-8E447242-F1C4-4A91-A897-7252088116DEQ64097897-FAABCB65-4DE1-4C14-BC9A-2CFEA4B9304DQ64100971-E2DAE9D2-8872-4F4A-8217-B1C7C5C03724Q64114213-ACC9FFE5-5273-43B3-9E02-AA3E6FDE8174Q84836935-28E8E972-EBBF-4F90-91BC-C44B6AF2796FQ88961041-ECB21326-E2FB-4464-BCD3-0918DE2BAC10Q89446943-6AE1AAD9-D364-4535-B352-8B574A741169Q90156140-F7CD73D1-E877-4A2E-8CD2-7C4DEF04E0A4Q90493756-3EFE2A9A-1263-4435-9909-CC36D91A6B8BQ90592695-E6F6E545-7B16-47B8-9AFD-64459BD0700FQ90716197-79FD2EB0-9DDB-4965-B9E9-DF06A45BF948Q91329177-57E62E94-EC82-497C-8167-7AD739E0CC92Q91775269-6EA1CF0B-FEC3-48CB-B979-87E1FDA36300
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Federica Morano
@ast
Federica Morano
@en
Federica Morano
@es
Federica Morano
@nl
Federica Morano
@sl
type
label
Federica Morano
@ast
Federica Morano
@en
Federica Morano
@es
Federica Morano
@nl
Federica Morano
@sl
prefLabel
Federica Morano
@ast
Federica Morano
@en
Federica Morano
@es
Federica Morano
@nl
Federica Morano
@sl
P1053
B-7910-2018
P106
P1153
55341990700
P21
P31
P496
0000-0002-5306-3596